Deutsche Bank analyst Justin Bowers lowered the firm’s price target on Maravai Lifesciences to $17 from $23 and keeps a Buy rating on the shares post the Q2 results and “tough cut” to guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRVI:
- Maravai Lifesciences price target lowered to $12 from $17 at Stifel
- Maravai Lifesciences price target lowered to $12 from $15 at BofA
- Maravai Lifesciences price target lowered to $11 from $18 at Baird
- Maravai Lifesciences downgraded to Sector Weight from Overweight at KeyBanc
- Maravai Lifesciences sees FY23 EPS 4c-8c, consensus 29c